Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Possibilities of Combination of Beta-blockers and Ivabradine in Patients with Stable Angina Pectoris

https://doi.org/10.20996/1819-6446-2019-15-5-663-669

Full Text:

Abstract

Aim. To evaluate the therapeutic efficacy of a combination of ivabradine and beta-blockers (BAB) in patients with stable angina, initially taking only BAB and not reaching the target heart rate (HR) due to the risk of hypotension.

Material and methods. A prospective observational post-registration study was performed at the Research Institute for Complex Issues of Cardiovascular Diseases. The study included 50 patients with stable angina pectoris (diagnosed by coronary angiography in combination with clinical manifestations of angina of functional class II-III according to the Canadian classification) and an initial sinus rhythm with a heart rate of more than 70 beats per minute. These patients have already taken BAB. Heart rate, the number of angina attacks, nitrate intake and quality of life indicators according to the questionnaire were evaluated as criteria for therapeutic efficacy.

Results. Taking the study drug in combination with BAB led to a significant decrease the average heart rate at rest by 20%, as well as after a six-minute walk test (TLC) in most patients (p<0.050), and a decrease in the total number of angina attacks per week from 5 to less than 1 (p<0.050) and the frequency of nitrate intake for the relief of angina attacks from 58% to 20% (p=0.001). Therapy with ivabradine (Bravadin) was well tolerated by patients: there were no adverse events in the observed sample of patients, patients had a high adherence to treatment (100% of the contents of handed out blisters were used). During the 3 months of follow-up, according to the EQ-5D-5L quality of life questionnaire, patients improved their perception of their own health level (p<0.050), the number of patients experiencing mild (p=0.034) and strong (p=0.041) mobility limitations decreased; strong (p=0.024) restriction in self-care, mild (p=0.041) and strong (p=0.024) restriction of daily activities, mild manifestation of pain (p=0.009) and mild anxiety (p=0.027) also were reduced compared with the initial questionnaires.

Conclusion. Ivabradine (Bravadin) in addition to BAB is an effective and safe antianginal therapy for the prevention of angina attacks by reducing the initially high heart rate in patients with angina pectoris of functional class II-III.

About the Authors

V. V. Kashtalap
Research Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University
Russian Federation

MD, PhD, Head of Laboratory of Pathophysiology of Multifocal Atherosclerosis, Sosnoviy bulv. 6, Kemerovo, 650002 

Associate Professor, Chair of Cardiology and Cardiovascular Surgery, Voroshilova ul. 22A, Kemerovo, 650029



O. L. Barbarash
Research Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University
Russian Federation

MD, PhD, Corresponding Member of the Russian Academy of Sciences, Director, Sosnoviy bulv. 6, Kemerovo, 650002;

Head of Chair of Cardiology and Cardiovascular Surgery, Voroshilova ul. 22A, Kemerovo, 650029



D. Yu. Sedykh
Research Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University
Russian Federation

MD, PhD, Researcher, Laboratory of Pathophysiology of Multifocal Atherosclerosis, Sosnoviy bulv. 6, Kemerovo, 650002; 

Cardiologist, Voroshilova ul. 22A, Kemerovo, 650029 



K. E. Krivoshapova
Research Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University
Russian Federation

MD, PhD, Researcher, Laboratory of Pathophysiology of Multifocal Atherosclerosis, Sosnoviy bulv. 6, Kemerovo, 650002;

Cardiologist, Voroshilova ul. 22A, Kemerovo, 650029 



D. P. Tsygankova
Research Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University
Russian Federation

MD, PhD, Researcher, Laboratory of Cardiovascular Diseases Epidemiology, Sosnoviy bulv. 6, Kemerovo, 650002;

Endocrinologist, Voroshilova ul. 22A, Kemerovo, 650029 



O. V. Tsygankova
Novosibirsk State Medical University
Russian Federation

MD, PhD, Professor, Chair of Emergency Therapy with Endocrinology and Occupational Pathology,

Krasniy prosp. 52, Novosibirsk, 630091



References

1. Members Task Force Members; Montalescot G., Sechtem U., Achenbach S., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34(38):2949-3003. DOI:10.1093/eurheartj/eht296.

2. Stable ischemic heart disease. Clinical recommendations (2016) [cited by Apr 15, 2019]. Available from: http://cr.rosminzdrav.ru/schema.html?id=133#/text (In Russ.).

3. Di Francesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53:399-406. DOI:10.1016/j.phrs.2006.03.006.

4. Sudgaeva O.A. Various approaches to the optimal medical therapy of stable angina with the use of ivabradine (coraxan). Медицинские Новости. 2016;5:17-22. (In Russ).

5. Povetkin S.V., Luneva J.V. Study of Clinical Efficacy of Original and Generic Drugs of Ivabradine in Patients with Stable Angina (Сomparative Study). Rational Pharmacotherapy in Cardiology 2018;14(1):34-39. DOI: 10.20996/1819-6446-2018-14-1-34-39 (In Russ).

6. Tardif J.C., Ponikowski P., Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30:540-8. DOI:10.1093/eurheartj/ehn571.

7. Fox K., Ford I., Steg P.G., et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807-16. DOI:10.1016/S0140-6736(08)61170-8.

8. Fox K., Ford I., Steg P.G., et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30:2337-45. DOI:10.1093/eurheartj/ehp358.

9. Swedberg K., Komajda M., Bohm M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875-85. DOI:10.1016/S0140-6736(10)61198-1.

10. Bohm M., Swedberg K., Komajda M., et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376:886-94. DOI:10.1016/S0140-6736(10)61259-7.

11. Swedberg K., Komajda M., Bohm M., et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Findings from the SHIFT (Systolic Heart failure treatment with the I(f ) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59:1938-45. DOI:10.1016/j.jacc.2012.01.020.

12. Kannel W.B., Kannel C., Paffenbarger R.S., Cupples L.A. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113:1489-94. DOI:10.1016/0002-8703(87)90666-1.

13. Fox K.M., Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol. 2011;8:369-79. DOI:10.1038/nrcardio.2011.58.

14. Komissarenko I.A., Samsonova N.G. Evaluation of the effectiveness and tolerance of ivabradine (coraxan) in patients with ischemic heart disease with metabolic syndrome. Effektivnaja Farmakoterapija. 2013;43:22-7 (In Russ.).

15. Fox K., Ford K., Steg P.G., et al. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. Eur Heart J. 2015;36(46):3291-6. DOI:10.1093/eurheartj/ehv451.

16. Vasyuk Y.A., Nesvetov V.V., Shkolnik E.L., et al. Possibilities of Ivabradine, a Selective Inhibitor of IonfChannels of Sinus Node, in Prevention of Anthracycline Cardiotoxicity in Patients with Breast Cancer. Rational Pharmacotherapy in Cardiology. 2017;13(2):184-90 (In Russ.) DOI:10.20996/1819-6446-2017-13-2-184-190.

17. Martin R.I., Pogoryelova O., Koref M.S., et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart. 2014;100(19):1506-10. DOI:10.1136/heartjnl-2014-305482.

18. Wongcharoen W., Ruttanaphol A., Gunapam S., Phromminitikul A. Ivabradine reduced ventricular rate in patients with non-paroxysmal atrial fibrillation. A Int Cardiol. 2016;224:252-5. DOI:10.1016/j.ijcard.2016.09.044.

19. Mert K.U., Mert G.O., Morrad B., et al. Effects of ivabradine and beta-blocker therapy on dobutamine-induced ventricular arrhythmias. Kardiol Pol. 2017;75(8):786-93. DOI:10.5603/KP.a2017.0094.

20. Werdan K., Ebelt H., Nuding S., et al. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol. 2012;101:365-73. DOI:10.1007/s00392-011-0402-4.


For citation:


Kashtalap V.V., Barbarash O.L., Sedykh D.Y., Krivoshapova K.E., Tsygankova D.P., Tsygankova O.V. Possibilities of Combination of Beta-blockers and Ivabradine in Patients with Stable Angina Pectoris. Rational Pharmacotherapy in Cardiology. 2019;15(5):663-669. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-5-663-669

Views: 23


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)